Atlas Trials

The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia

Clinical trial NCT02707497 · UNKNOWN

Trial details

NCT number
NCT02707497
Sponsor
Ruilan Wang
Status
UNKNOWN
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
SepsisThrombocytopenia
Start date
2019-04-01
Primary completion
2024-08-31
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.